Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.[1]
- Market Cap ₹ 1,154 Cr.
- Current Price ₹ 7,834
- High / Low ₹ 8,747 / 1,711
- Stock P/E 94.3
- Book Value ₹ 500
- Dividend Yield 0.03 %
- ROCE 68.8 %
- ROE 66.1 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 63.6%
- Debtor days have improved from 51.3 to 39.3 days.
- Promoter holding has increased by 1.24% over last quarter.
Cons
- Stock is trading at 15.7 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
|---|---|---|---|---|---|
| 12 | 18 | 25 | 45 | 54 | |
| 12 | 18 | 21 | 34 | 39 | |
| Operating Profit | 0 | 1 | 4 | 11 | 15 |
| OPM % | 3% | 4% | 17% | 23% | 28% |
| 1 | 1 | 1 | 2 | 2 | |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 |
| Profit before tax | 1 | 1 | 5 | 11 | 16 |
| Tax % | 27% | 25% | 26% | 26% | |
| 1 | 1 | 3 | 8 | 12 | |
| EPS in Rs | 810.00 | 1,060.00 | 34.30 | 78.34 | 93.85 |
| Dividend Payout % | 0% | 0% | 0% | 3% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 56% |
| TTM: | 56% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 119% |
| TTM: | 122% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 64% |
| Last Year: | 66% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|---|---|
| Equity Capital | 0 | 0 | 1 | 1 | 1 |
| Reserves | 2 | 3 | 6 | 18 | 72 |
| 0 | 0 | 0 | 8 | 2 | |
| 3 | 8 | 9 | 8 | 12 | |
| Total Liabilities | 5 | 11 | 16 | 35 | 88 |
| 0 | 0 | 0 | 3 | 3 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 3 | 21 | 21 |
| 5 | 11 | 12 | 11 | 64 | |
| Total Assets | 5 | 11 | 16 | 35 | 88 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|
| 1 | -0 | 5 | 5 | |
| -1 | -0 | -5 | -15 | |
| 0 | -0 | -0 | 12 | |
| Net Cash Flow | 1 | -0 | 0 | 2 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|
| Debtor Days | 50 | 71 | 43 | 39 |
| Inventory Days | 23 | 36 | 47 | 5 |
| Days Payable | 68 | 164 | 139 | 60 |
| Cash Conversion Cycle | 5 | -56 | -48 | -16 |
| Working Capital Days | 22 | -18 | -38 | 8 |
| ROCE % | 46% | 92% | 69% |
Business Segments
A) APIs (84.5% of FY22 revenue)[1] Co has 54 products in this segment
B) Finished Pharmaceutical Formulations(15.5% of FY22 revenue)[1]